GW&K Investment Management LLC Sells 6,207 Shares of AbbVie Inc. $ABBV

GW&K Investment Management LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 375,778 shares of the company’s stock after selling 6,207 shares during the period. AbbVie comprises 0.8% of GW&K Investment Management LLC’s holdings, making the stock its 23rd largest holding. GW&K Investment Management LLC’s holdings in AbbVie were worth $87,008,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Norges Bank bought a new position in AbbVie during the 2nd quarter worth $4,288,200,000. Laurel Wealth Advisors LLC grew its holdings in shares of AbbVie by 18,384.4% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after purchasing an additional 5,675,095 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of AbbVie by 169.3% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after purchasing an additional 2,969,202 shares during the period. Finally, Raymond James Financial Inc. raised its stake in AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase‑3 AFFIRM results for risankizumab in moderately‑to‑severely active Crohn’s disease — higher clinical remission and endoscopic response vs. placebo. This materially strengthens AbbVie’s immunology growth runway (Skyrizi label expansion) and has driven valuation attention and buying interest. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: Regulatory/portfolio wins: AbbVie reported FDA approval for an oral VENCLEXTA + acalabrutinib combo in previously untreated CLL and is advancing venetoclax into a Phase‑2 program in rare blood cancers (Japan). These expand hematology revenue potential and diversify growth beyond immunology. AbbVie’s New Data And Approval Test Growth And Valuation Story
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) published Medical Weight Loss data showing shifting patient demand that supports aesthetic product adoption and long‑term revenue diversification. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA
• Neutral Sentiment: Market commentary/technicals: Analyst and market pieces show ABBV stabilizing near resistance levels — useful for short‑term traders but not a fundamental catalyst. AbbVie: Stabilizes Near $233 While Testing Resistance
• Neutral Sentiment: Investor events: Management will present at Leerink (Mar 10) and recently at TD Cowen — watch these for updated guidance, commercialization cadence for Skyrizi/Rinvoq, and use of capital commentary. AbbVie to Present at the Leerink Partners Global Healthcare Conference
• Negative Sentiment: Large senior‑notes issuance: AbbVie completed an underwritten public notes offering totaling roughly $7.5–$8.0 billion. Increased debt issuance can pressure credit metrics and investor sentiment despite likely strategic uses (refinancing, liquidity). Monitor yields and management commentary on use of proceeds. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Negative Sentiment: Policy/legal headwind: AbbVie lost its bid to block Tennessee’s 340B law, which could pressure pricing/reimbursement dynamics in certain channels and adds regulatory risk to the top‑line outlook. AbbVie loses bid to block Tennessee 340B law

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Piper Sandler boosted their target price on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Finally, Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $253.15.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.25% of the stock is owned by corporate insiders.

AbbVie Trading Up 0.9%

ABBV opened at $235.90 on Thursday. The company has a market cap of $417.11 billion, a P/E ratio of 99.96, a PEG ratio of 0.81 and a beta of 0.34. The company’s 50 day moving average is $224.68 and its 200-day moving average is $223.75. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.9%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.